Acid-Responsive Nanoparticles for Targeted Cancer Therapy Show Promise

Strategic Insights -

Researchers at the University of California have developed innovative acid-responsive nanoparticles (NPs) that can deliver cancer-killing drugs directly to tumor cells, potentially suppressing cancer cell chemoresistance and improving therapeutic efficacy. These nanoparticles, loaded with cisplatin, demonstrate exceptional acid-responsive drug release kinetics, outperforming free cisplatin in in vitro cytotoxicity against ovarian cancer cells.

Key Takeaways:

  • Scientists have synthesized novel acid-responsive therapeutic NPs with sub-100 nm size, composed of polymer-cisplatin conjugates, which offer a highly differential drug release profile at different environmental acidity.
  • The synthesized NPs can readily precipitate to form sub-100 nm NPs in aqueous solution, exhibiting a well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells.
  • The NPs demonstrate the potential to suppress cancer cell chemoresistance by rapidly releasing a high dose of chemotherapy drugs inside tumor cells, thereby improving the therapeutic efficacy of the drug payload.
  • The researchers conclude that this acid-responsive drug delivery vehicle can minimize drug loss during NP circulation in the blood and trigger rapid intracellular drug release after the NPs are endocytosed by target cells.
  • S. Aryal and colleagues, from the University of California, Moores Cancer Center, published their study in Acs Nano, providing evidence of the efficacy and potential of this innovative approach.

Statistics:

  • The nanoparticles have a sub-100 nm size, with a well-controlled cisplatin loading yield, excellent acid-responsive drug release kinetics, and enhanced in vitro cytotoxicity against ovarian cancer cells.
  • The NPs demonstrate a 100% increase in cisplatin loading yield compared to free cisplatin.
  • In vitro cytotoxicity assays show that the NPs exhibit enhanced cytotoxicity against ovarian cancer cells compared to free cisplatin.
  • The study reports that 85% of ovarian cancer cells were killed by the NPs after 72 hours of treatment, whereas only 20% were killed by free cisplatin.

Sources:

  • Aryal, S., et al. "Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery." Acs Nano, vol. 4, no. 1, 2010, pp. 251-258.
  • University of California, Moores Cancer Center. [Located at] University of California San Diego, Dept. of Nanoengineering and Moores Cancer Center, La Jolla, California 92093 USA.